← Back to Search

Virus Therapy

Nativis Voyager RFE Therapy for Glioblastoma

N/A
Waitlist Available
Research Sponsored by Nativis, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through one month following investigational treatment
Awards & highlights

Study Summary

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab. Safety and clinical utility will be evaluated.

Eligible Conditions
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of any adverse events associated with the investigational therapy.
Secondary outcome measures
Clinical Utility: OS
Clinical Utility: PFS

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nativis Voyager RFE TherapyExperimental Treatment1 Intervention
Subjects will be treated with Nativis Voyager therapy until tumor progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nativis Voyager RFE Therapy
2014
N/A
~40

Find a Location

Who is running the clinical trial?

Nativis, Inc.Lead Sponsor
2 Previous Clinical Trials
48 Total Patients Enrolled
2 Trials studying Glioblastoma
48 Patients Enrolled for Glioblastoma
Donna Morgan Murray, PhDStudy DirectorNativis, Inc.
2 Previous Clinical Trials
48 Total Patients Enrolled
2 Trials studying Glioblastoma
48 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Kansas
What site did they apply to?
University of Kansas Medical Center (KUMC)
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)
2014. "A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02296580.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top